{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T03:40:29Z","timestamp":1773114029625,"version":"3.50.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T00:00:00Z","timestamp":1588723200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T00:00:00Z","timestamp":1588723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["DA039167"],"award-info":[{"award-number":["DA039167"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["DA018151"],"award-info":[{"award-number":["DA018151"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["DA045011"],"award-info":[{"award-number":["DA045011"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["AA016179"],"award-info":[{"award-number":["AA016179"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s00213-020-05519-7","type":"journal-article","created":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T02:02:31Z","timestamp":1588730551000},"page":"2075-2087","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Quantification of observable behaviors induced by typical and atypical kappa-opioid receptor\u00a0agonists in male rhesus monkeys"],"prefix":"10.1007","volume":"237","author":[{"given":"S. L.","family":"Huskinson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. M.","family":"Platt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Brasfield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. E.","family":"Follett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. E.","family":"Prisinzano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. E.","family":"Blough","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. B.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,6]]},"reference":[{"key":"5519_CR1","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1208\/s12248-009-9105-4","volume":"11","author":"JV Aldrich","year":"2009","unstructured":"Aldrich JV, McLaughlin JP (2009) Peptide kappa opioid receptor ligands: potential for drug development. AAPS J 11:312\u2013322. https:\/\/doi.org\/10.1208\/s12248-009-9105-4","journal-title":"AAPS J"},{"key":"5519_CR2","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1097\/00000542-200204000-00031","volume":"96","author":"American Society of Anesthesiologists","year":"2002","unstructured":"American Society of Anesthesiologists (2002) An updated report by the American Society of Anesthesiologists task force on sedation and analgesia by non-anesthesiologists practice: guidelines for sedation and analgesia by non-anesthesiologists. Anesthesiol 96:1004\u20131017","journal-title":"Anesthesiol"},{"key":"5519_CR3","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s00213-008-1458-3","volume":"203","author":"LE Baker","year":"2009","unstructured":"Baker LE, Panos JJ, Killinger BA, Peet MM, Bell LM, Haliw LA, Walker SL (2009) Comparison of the discriminative stimulus effects of salvinorin A and its derivatives to U69,593 and U50,488 in rats. Psychopharmacol 203:203\u2013211. https:\/\/doi.org\/10.1007\/s00213-008-1458-3","journal-title":"Psychopharmacol"},{"key":"5519_CR4","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3390\/ph12020095","volume":"12","author":"TC Beck","year":"2019","unstructured":"Beck TC, Hapstack MA, Beck KR, Dix TA (2019) Therapeutic potential of kappa opioid agonists. Pharmaceuticals 12:95. https:\/\/doi.org\/10.3390\/ph12020095","journal-title":"Pharmaceuticals"},{"key":"5519_CR5","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/s41386-018-0125-6","volume":"44","author":"JB Becker","year":"2019","unstructured":"Becker JB, Chartoff E (2019) Sex differences in neural mechanisms mediating reward and addiction. Neuropsychopharmacol 44:166\u2013183. https:\/\/doi.org\/10.1038\/s41386-018-0125-6","journal-title":"Neuropsychopharmacol"},{"key":"5519_CR6","doi-asserted-by":"publisher","first-page":"ra117","DOI":"10.1126\/scisignal.aai8441","volume":"9","author":"TF Brust","year":"2016","unstructured":"Brust TF, Morgenweck J, Kim SA, Rose JH, Locke JL, Schmid CL, Zhou L, Stahl EL, Cameron MD, Scarry SM, Aube J, Jones SR, Martin TJ, Bohn LM (2016) Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria. Sci Signal 9:ra117. https:\/\/doi.org\/10.1126\/scisignal.aai8441","journal-title":"Sci Signal"},{"key":"5519_CR7","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1124\/jpet.106.112417","volume":"320","author":"ER Butelman","year":"2007","unstructured":"Butelman ER, Mandau M, Tidgewell K, Prisinzano TE, Yuferov V, Kreek MJ (2007) Effects of salvinorin A, a kappa-opioid hallucinogen, on a neuroendocrine biomarker assay in nonhuman primates with high kappa-receptor homology to humans. J Pharmacol Exp Ther 320:300\u2013306. https:\/\/doi.org\/10.1124\/jpet.106.112417","journal-title":"J Pharmacol Exp Ther"},{"key":"5519_CR8","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1124\/jpet.108.145342","volume":"328","author":"ER Butelman","year":"2009","unstructured":"Butelman ER, Prisinzano TE, Deng H, Rus S, Kreek MJ (2009) Unconditioned behavioral effects of the powerful k-opioid hallucinogen salvinorin A in nonhuman primates: fast onset and entry into cerebrospinal fluid. J Pharmacol Exp Ther 328:588\u2013597. https:\/\/doi.org\/10.1124\/jpet.108.145342","journal-title":"J Pharmacol Exp Ther"},{"key":"5519_CR9","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s00213-009-1771-5","volume":"210","author":"ER Butelman","year":"2010","unstructured":"Butelman ER, Rus S, Prisinzano TE, Kreek MJ (2010) The discriminative effects of the kappa-opioid hallucinogen salvinorin A in nonhuman primates: dissociation from classic hallucinogen effects. Psychopharmacol 210:253\u2013262. https:\/\/doi.org\/10.1007\/s00213-009-1771-5","journal-title":"Psychopharmacol"},{"key":"5519_CR10","doi-asserted-by":"publisher","first-page":"466","DOI":"10.3389\/fnins.2015.00466","volume":"9","author":"EH Chartoff","year":"2015","unstructured":"Chartoff EH, Mavrikaki M (2015) Sex differences in kappa opioid receptor function and their potential impact on addiction. Front Neurosci 9:466. https:\/\/doi.org\/10.3389\/fnins.2015.00466","journal-title":"Front Neurosci"},{"key":"5519_CR11","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/s41583-018-0028-x","volume":"19","author":"E Darcq","year":"2018","unstructured":"Darcq E, Kieffer BL (2018) Opioid receptors: drivers to addiction? Nat Rev Neurosci 19:499\u2013514. https:\/\/doi.org\/10.1038\/s41583-018-0028-x","journal-title":"Nat Rev Neurosci"},{"key":"5519_CR12","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.ejphar.2015.07.018","volume":"763","author":"S Dogra","year":"2015","unstructured":"Dogra S, Yadav PN (2015) Biased agonism at kappa opioid receptors: implication in pain and mood disorders. Eur J Pharmacol 763:184\u2013190. https:\/\/doi.org\/10.1016\/j.ejphar.2015.07.018","journal-title":"Eur J Pharmacol"},{"key":"5519_CR13","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1124\/jpet.118.249250","volume":"366","author":"AN Duke","year":"2018","unstructured":"Duke AN, Meng Z, Platt DM, Atack JR, Dawson GR, Reynolds DS, Tiruveedhula V, Li G, Stephen MR, Sieghart W, Cook JM, Rowlett JK (2018) Evidence that sedative effects of benzodiazepines involve unexpected GABAA receptor subtypes: quantitative observation studies in rhesus monkeys. J Pharmacol Exp Ther 366:145\u2013157. https:\/\/doi.org\/10.1124\/jpet.118.249250","journal-title":"J Pharmacol Exp Ther"},{"key":"5519_CR14","doi-asserted-by":"publisher","first-page":"3590","DOI":"10.1021\/acschemneuro.9b00195","volume":"10","author":"AD Dunn","year":"2019","unstructured":"Dunn AD, Reed B, Erazo J, Ben-Ezra A, Kreek MJ (2019) Signaling properties of structurally diverse kappa opioid receptor ligands: toward in vitro models of in vivo responses. ACS Chem Neurosci 10:3590\u20133600. https:\/\/doi.org\/10.1021\/acschemneuro.9b00195","journal-title":"ACS Chem Neurosci"},{"key":"5519_CR15","unstructured":"Dykstra LA, Gmerek DE, Winger G, Woods JH (1987) Kappa opioids in rhesus monkeys. I. Diuresis, sedation, analgesia and discriminative stimulus effects. J Pharmacol Exp Ther 242:413\u2013420"},{"key":"5519_CR16","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/S0024-3205(99)00417-8","volume":"65","author":"T Endoh","year":"1999","unstructured":"Endoh T, Matsuura H, Tajima A, Izumimoto N, Tajima C, Suzuki T et al (1999) Potent antinociceptive effects of TRK-820, a novel k-opioid receptor agonist. Life Sci 65:1685\u20131694. https:\/\/doi.org\/10.1016\/S0024-3205(99)00417-8","journal-title":"Life Sci"},{"key":"5519_CR17","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1254\/jjp.85.282","volume":"85","author":"T Endoh","year":"2001","unstructured":"Endoh T, Tajima A, Izumimoto N, Suzuki T, Saitoh A, Suzuki T et al (2001) TRK-820, a selective k-opioid agonist, produces potent antinociception in cynomolgus monkeys. Jpn J Pharmacol 85:282\u2013290. https:\/\/doi.org\/10.1254\/jjp.85.282","journal-title":"Jpn J Pharmacol"},{"key":"5519_CR18","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1196\/annals.1316.050","volume":"1025","author":"K Hasebe","year":"2004","unstructured":"Hasebe K, Kawai K, Suzuki T, Kawamura K, Tanaka T, Narita M, Nagase H, Suzuki T (2004) Possible pharmacotherapy of the opioid kappa receptor agonist for drug dependence. Ann N Y Acad Sci 1025:404\u2013413. https:\/\/doi.org\/10.1196\/annals.1316.050","journal-title":"Ann N Y Acad Sci"},{"key":"5519_CR19","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1037\/pha0000098","volume":"24","author":"SL Huskinson","year":"2016","unstructured":"Huskinson SL, Myerson J, Green L, Rowlett JK, Woolverton WL, Freeman KB (2016) Shallow discounting of delayed cocaine by male rhesus monkeys when immediate food is the choice alternative. Exp Clin Psychopharmacol 24:456\u2013463. https:\/\/doi.org\/10.1037\/pha0000098","journal-title":"Exp Clin Psychopharmacol"},{"key":"5519_CR20","doi-asserted-by":"publisher","first-page":"172702","DOI":"10.1016\/j.ejphar.2019.172702","volume":"864","author":"S Inan","year":"2019","unstructured":"Inan S, Huerta AT, Jensen LE, Dun NJ, Cowan A (2019) Nalbuphine, a kappa opioid receptor agonist and mu opioid receptor antagonist attenuates pruritus, decreases IL-31, and increases IL-10 in mice with contact dermatitis. Eur J Pharmacol 864:172702. https:\/\/doi.org\/10.1016\/j.ejphar.2019.172702","journal-title":"Eur J Pharmacol"},{"key":"5519_CR21","doi-asserted-by":"publisher","first-page":"249","DOI":"10.2147\/CCID.S55942","volume":"8","author":"S Inui","year":"2015","unstructured":"Inui S (2015) Nalfurafine hydrochloride to treat pruritus: a review. Clin Cosmet Investig Dermatol 8:249\u2013255. https:\/\/doi.org\/10.2147\/CCID.S55942","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"5519_CR22","doi-asserted-by":"publisher","first-page":"e0178991","DOI":"10.1371\/journal.pone.0178991","volume":"12","author":"K Kamimura","year":"2017","unstructured":"Kamimura K, Yokoo T, Kamimura H, Sakamaki A, Abe S, Tsuchiya A, Takamura M, Kawai H, Yamagiwa S, Terai S (2017) Long-term efficacy and safety of nalfurafine hydrochloride on pruritus in chronic liver disease patients: patient-reported outcome based analyses. PLoS One 12:e0178991. https:\/\/doi.org\/10.1371\/journal.pone.0178991","journal-title":"PLoS One"},{"key":"5519_CR23","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1124\/jpet.118.255661","volume":"371","author":"SW Kaski","year":"2019","unstructured":"Kaski SW, White AN, Gross JD, Trexler KR, Wix K, Harland AA, Prisinzano TE, Aube J, Kinsey SG, Kenakin T, Siderovski DP, Setola V (2019) Preclinical testing of nalfurafine as an opioid-sparing adjuvant that potentiates analgesia by the mu opioid receptor-targeting agonist morphine. J Pharmacol Exp Ther 371:487\u2013499. https:\/\/doi.org\/10.1124\/jpet.118.255661","journal-title":"J Pharmacol Exp Ther"},{"key":"5519_CR24","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s00213-010-1819-6","volume":"210","author":"B Kivell","year":"2010","unstructured":"Kivell B, Prisinzano TE (2010) Kappa opioids and the modulation of pain. Psychopharmacol 210:109\u2013119. https:\/\/doi.org\/10.1007\/s00213-010-1819-6","journal-title":"Psychopharmacol"},{"key":"5519_CR25","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1124\/jpet.108.143925","volume":"328","author":"MC Ko","year":"2009","unstructured":"Ko MC, Husbands SM (2009) Effects of atypical kappa-opioid receptor agonists on Intrathecal morphine-induced itch and analgesia in primates. J Pharmacol Exp Ther 328:193\u2013200. https:\/\/doi.org\/10.1124\/jpet.108.143925","journal-title":"J Pharmacol Exp Ther"},{"key":"5519_CR26","first-page":"260","volume":"288","author":"MJ Kreek","year":"1999","unstructured":"Kreek MJ, Schluger J, Borg L, Gunduz M, Ho A (1999) Dynorphin A1-13 causes elevation of serum levels of prolactin through an opioid receptor mechanism in humans: gender differences and implications for modulation of dopaminergic tone in the treatment of addictions. J Pharmacol Exp Ther 288:260\u2013269","journal-title":"J Pharmacol Exp Ther"},{"key":"5519_CR27","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s00213-017-4758-7","volume":"235","author":"ML Lazenka","year":"2018","unstructured":"Lazenka ML, Moerke MJ, Townsend EA, Freeman KB, Carroll FI, Negus SS (2018) Dissociable effects of the kappa opioid receptor agonist nalfurafine on pain\/itch-stimulated and pain\/itch-depressed behaviors in male rats. Psychopharmacol 235:203\u2013213. https:\/\/doi.org\/10.1007\/s00213-017-4758-7","journal-title":"Psychopharmacol"},{"key":"5519_CR28","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1007\/s00213-018-4920-x","volume":"235","author":"V Minervini","year":"2018","unstructured":"Minervini V, Lu HY, Padarti J, Osteicoechea DC, France CP (2018) Interactions between kappa and mu opioid receptor agonists: effects of the ratio of drugs in mixtures. Psychopharmacol 235:2245\u20132256. https:\/\/doi.org\/10.1007\/s00213-018-4920-x","journal-title":"Psychopharmacol"},{"key":"5519_CR29","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3389\/fphar.2019.00407","volume":"10","author":"KL Mores","year":"2019","unstructured":"Mores KL, Cummins BR, Cassell RJ, van Rijn RM (2019) A review of the therapeutic potential of recently developed G protein-biased kappa agonists. Front Pharmacol 10:407. https:\/\/doi.org\/10.3389\/fphar.2019.00407","journal-title":"Front Pharmacol"},{"key":"5519_CR30","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1054\/jpai.2002.124734","volume":"3","author":"SS Negus","year":"2002","unstructured":"Negus SS, Zuzga DS, Mello NK (2002) Sex differences in opioid antinociception in rhesus monkeys: antagonism of fentanyl and U50,488 by quadazocine. J Pain 3:218\u2013226. https:\/\/doi.org\/10.1054\/jpai.2002.124734","journal-title":"J Pain"},{"key":"5519_CR31","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1037\/a0013088","volume":"16","author":"SS Negus","year":"2008","unstructured":"Negus SS, Schrode K, Stevenson GW (2008) Mu\/kappa opioid interactions in rhesus monkeys: implications for analgesia and abuse liability. Exp Clin Psychopharmacol 16:386\u2013399. https:\/\/doi.org\/10.1037\/a0013088","journal-title":"Exp Clin Psychopharmacol"},{"key":"5519_CR32","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/ajp.1350280205","volume":"28","author":"MA Novak","year":"1992","unstructured":"Novak MA, O\u2019Neill P, Suomi SJ (1992) Adjustments and adaptations to indoor and outdoor environments: continuity and change in young adult rhesus monkeys. Am J Primatol 28:124\u2013138. https:\/\/doi.org\/10.1002\/ajp.1350280205","journal-title":"Am J Primatol"},{"key":"5519_CR33","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/(SICI)1098-2345(1998)46:3<213::AID-AJP3>3.0.CO;2-L","volume":"46","author":"MA Novak","year":"1998","unstructured":"Novak MA, Kinsey JH, Jorgensen MJ, Hazen TJ (1998) Effects of puzzle feeders on pathological behavior in individually housed rhesus monkeys. Am J Primatol 46:213\u2013227. https:\/\/doi.org\/10.1002\/(SICI)1098-2345(1998)46:3<213::AID-AJP3>3.0.CO;2-L","journal-title":"Am J Primatol"},{"key":"5519_CR34","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1126\/science.3016896","volume":"233","author":"A Pfeiffer","year":"1986","unstructured":"Pfeiffer A, Brantl V, Herz A, Emrich HM (1986) Psychotomimesis mediated by kappa opiate receptors. Science 233:774\u2013776. https:\/\/doi.org\/10.1126\/science.3016896","journal-title":"Science"},{"key":"5519_CR35","doi-asserted-by":"publisher","first-page":"555","DOI":"10.2340\/00015555-1353","volume":"92","author":"NQ Phan","year":"2012","unstructured":"Phan NQ, Lotts T, Antal A, Bernhard JD, Stander S (2012) Systemic kappa opioid receptor agonists in the treatment of chronic pruritus: a literature review. Acta Derm Venereol 92:555\u2013560. https:\/\/doi.org\/10.2340\/00015555-1353","journal-title":"Acta Derm Venereol"},{"key":"5519_CR36","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s00213-002-1189-9","volume":"164","author":"DM Platt","year":"2002","unstructured":"Platt DM, Rowlett JK, Spealman RD, Cook J, Ma C (2002) Selective antagonism of the ataxic effects of zolpidem and triazolam by the GABAA\/alpha1-preferring antagonist beta-CCt in squirrel monkeys. Psychopharmacol 164:151\u2013159. https:\/\/doi.org\/10.1007\/s00213-002-1189-9","journal-title":"Psychopharmacol"},{"key":"5519_CR37","doi-asserted-by":"publisher","first-page":"E592","DOI":"10.1208\/aapsj070361","volume":"7","author":"TE Prisinzano","year":"2005","unstructured":"Prisinzano TE, Tidgewell K, Harding WW (2005) Kappa opioids as potential treatments for stimulant dependence. AAPS J 7:E592\u2013E599. https:\/\/doi.org\/10.1208\/aapsj070361","journal-title":"AAPS J"},{"key":"5519_CR38","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.bbr.2014.01.003","volume":"262","author":"CF Robles","year":"2014","unstructured":"Robles CF, McMackin MZ, Campi KL, Doig IE, Takahashi EY, Pride MC, Trainor BC (2014) Effects of kappa opioid receptors on conditioned place aversion and social interaction in males and females. Behav Brain Res 262:84\u201393. https:\/\/doi.org\/10.1016\/j.bbr.2014.01.003","journal-title":"Behav Brain Res"},{"key":"5519_CR39","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1111\/acer.12018","volume":"37","author":"D Ruedi-Bettschen","year":"2013","unstructured":"Ruedi-Bettschen D, Rowlett JK, Rallapalli S, Clayton T, Cook JM, Platt DM (2013) Modulation of alpha5 subunit-containing GABAA receptors alters alcohol drinking by rhesus monkeys. Alcohol Clin Exp Res 37:624\u2013634. https:\/\/doi.org\/10.1111\/acer.12018","journal-title":"Alcohol Clin Exp Res"},{"key":"5519_CR40","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.biopsych.2013.07.042","volume":"76","author":"SE Russell","year":"2014","unstructured":"Russell SE, Rachlin AB, Smith KL, Muschamp J, Berry L, Zhao Z, Chartoff EH (2014) Sex differences in sensitivity to the depressive-like effects of the kappa opioid receptor agonist U-50488 in rats. Biol Psychiatry 76:213\u2013222. https:\/\/doi.org\/10.1016\/j.biopsych.2013.07.042","journal-title":"Biol Psychiatry"},{"key":"5519_CR41","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.cellsig.2017.01.016","volume":"32","author":"SS Schattauer","year":"2017","unstructured":"Schattauer SS, Kuhar JR, Song A, Chavkin C (2017) Nalfurafine is a G-protein biased agonist having significantly greater bias at the human than rodent form of the kappa opioid receptor. Cell Signal 32:59\u201365. https:\/\/doi.org\/10.1016\/j.cellsig.2017.01.016","journal-title":"Cell Signal"},{"key":"5519_CR42","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1007\/s00213-017-4652-3","volume":"234","author":"EA Townsend","year":"2017","unstructured":"Townsend EA, Naylor JE, Negus SS, Edwards SR, Qureshi HN, McLendon HW, McCurdy CR, Kapanda CN, do Carmo JM, da Silva FS, Hall JE, Sufka KJ, Freeman KB (2017) Effects of nalfurafine on the reinforcing, thermal antinociceptive, and respiratory-depressant effects of oxycodone: modeling an abuse-deterrent opioid analgesic in rats. Psychopharmacol 234:2597\u20132605. https:\/\/doi.org\/10.1007\/s00213-017-4652-3","journal-title":"Psychopharmacol"},{"key":"5519_CR43","first-page":"41","volume":"285","author":"EM Weerts","year":"1998","unstructured":"Weerts EM, Ator NA, Grech DM, Griffiths RR (1998) Zolpidem physical dependence assessed across increasing doses under a one-daily dosing regimen in baboons. J Pharmacol Exp Ther 285:41\u201353","journal-title":"J Pharmacol Exp Ther"},{"key":"5519_CR44","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/s41580-018-0049-3","volume":"19","author":"D Wootten","year":"2018","unstructured":"Wootten D, Christopoulus A, Marti-Solano M, Babu MM, Sexton PM (2018) Mechanisms of signalling and biased agonism in G protein-coupled receptors. Nat Rev Mol Cell Biol 19:638\u2013653. https:\/\/doi.org\/10.1038\/s41580-018-0049-3","journal-title":"Nat Rev Mol Cell Biol"},{"key":"5519_CR45","doi-asserted-by":"publisher","unstructured":"Zamarripa CA, Naylor JE, Huskinson SL, Townsend EA, Prisinzano TE, Freeman KB (2020) Kappa opioid agonists reduce oxycodone selfadministration in male rhesus monkeys. Psychopharmacology. https:\/\/doi.org\/10.1007\/s00213-020-05473-4","DOI":"10.1007\/s00213-020-05473-4"},{"key":"5519_CR46","doi-asserted-by":"publisher","first-page":"36703","DOI":"10.1074\/jbc.M113.504381","volume":"288","author":"L Zhou","year":"2013","unstructured":"Zhou L, Lovell KM, Frankowski KJ, Slauson SR, Phillips AM, Streicher JM, Stahl E, Schmid CL, Hodder P, Madoux F, Cameron MD, Prisinzano TE, Aube J, Bohn LM (2013) Development of functionally selective, small molecule agonists at kappa opioid receptors. J Biol Chem 288:36703\u201336716. https:\/\/doi.org\/10.1074\/jbc.M113.504381","journal-title":"J Biol Chem"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-020-05519-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-020-05519-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-020-05519-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T23:23:02Z","timestamp":1620256982000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00213-020-05519-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,6]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["5519"],"URL":"https:\/\/doi.org\/10.1007\/s00213-020-05519-7","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,6]]},"assertion":[{"value":"21 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures were approved by the University of Mississippi Medical Center\u2019s Institutional Animal Care and Use Committee and were conducted in accordance with the National Research Council\u2019s Guide for Care and Use of Laboratory Animals (8th edition, 2011).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The author declares that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}